

Supplementary disclosures and information regarding item 5



Dr. Anna C. Eichhorn

**Member of the BRAIN Biotech AG Supervisory Board since March 9, 2017;
Vice Chairwoman since March, 5, 2020; appointed until the end of AGM in FY 2024/25**

- **Member of the nomination committee** (chair)
- **Key areas of expertise:** Entrepreneurship; New business areas; Sector; Internationality

Born in 1972, Nationality: German

Education

- **Foundation course in chemistry and biology**
- **1998 degree in biochemistry** from Johann Wolfgang Goethe University, Frankfurt/Main, Germany
- **2003 academic degree of Disputation**

Professional Career

- **2001 – today: Co-Founder humatrix AG, Frankfurt/Main - today in Pfungstadt, Germany** (*not listed*)
Chief Technology Officer (CTO)
Since 2012: Chief Executive Officer (CEO)
- **2014 – today: House of Pharma & Healthcare Association, Frankfurt/Main, Germany** - Management Board Member
- **2007 – today: Initiative gesundheitswirtschaft-rhein-main Association, Frankfurt/Main, Germany** - Deputy Chief Executive Officer (CEO)
- **2006 – 2016: European Journal of Clinical Pharmacology (EJCP), Germany** - Scientific consultant
- **2023 – today: Charlotte Fresenius University of Applied Sciences in Wiesbaden, Germany** - lecturer

Further memberships of statutory Supervisory Boards in Germany:

None

Further memberships in comparable German and foreign Supervisory Boards:

Member of the Supervisory Board of the Frankfurter Innovationszentrum Biotechnologie GmbH (FiZ), Frankfurt/Main, Germany

In addition to the above information, with regard to C.13 of the German Corporate Governance Code, it is stated that, in the Supervisory Board's opinion, Dr. Anna Eichhorn has no other personal or business relations with the company or its Group companies, the corporate bodies of the company or a shareholder with a significant interest in the company that would require disclosure under C.13 of the German Corporate Governance Code. In the Supervisory Board's opinion, Dr. Eichhorn is to be regarded as independent in the meaning of the German Corporate Governance Code. Moreover, the Supervisory Board has assured itself of the proposed candidates' ability to devote the expected amount of time in each case.